Cologuard Reports Coverage by Several Commercial Health Plans in Q1 2015

Exact Sciences Corp. reported expanded patient access to Cologuard as a result of several insurers now covering the test.

In a release, the Company noted that Cologuard is now covered for more than 90 million Medicare and commercial lives across the U.S.

Since the start of 2015, several insurers began covering Cologuard as a noninvasive colon cancer screening test.

"As adoption of Cologuard grows rapidly among leading insurance providers, Exact Sciences is encouraged that the medical community continues to believe in the value of offering this additional noninvasive screening test to average risk patients," said Kevin Conroy, Chairman and CEO of Exact Sciences. "With expanded patient access to the test, we are excited about the opportunity to reach millions of people and continue to support awareness and options for colorectal cancer screening nationwide."

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular

More information: